Advertisement

Clinical perspectives of cholecystokinin antagonists in pain management

  • M. Amanzio
  • F. Benedetti
Part of the Topics in Anaesthesia and Critical Care book series (TIACC)

Abstract

Cholecystokinin (CCK) is a peptide widely distributed in the central nervous system. Since its characterization in the porcine intestine, evidence has accumulated that it plays an essential role in several brain functions such as nociception, anxiety, memory, sleep and dopamine modulation. In mammalian brain, CCK is mainly found as an octapeptide (CCK-8) and tetrapeptide (CCK-4) and its effects are mediated by two types of receptors: CCK-A and CCK-B [1, 2]. CCK-8 acts at both receptors whereas CCK-4 shows its main activity at the CCK-B receptors. The distribution of the type-A and type-B receptors shows species differences and this fact has important clinical implications [3]. For example, CCKB binding sites are predominant in the spinal cord of rodents whereas CCK-A receptors prevail in the spinal cord of primates and humans. Therefore, the original nomenclature of peripheral alimentary (type A) and brain (type B) receptors no longer holds. It should be pointed out that, whereas the gene cckA encodes for the CCK-A receptor, the gene cckB encodes for both the CCK-B and gastrin receptor, thus indicating that the type-B binding site is better defined as CCK-B-gastrin receptor.

Keywords

Endogenous Opioid Morphine Analgesia Placebo analgeSia Gastrin Receptor Dopamine Modulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Woodruff GN, Hughes J (1991) Cholecystokinin antagonists. Ann Rev Pharmacol Toxicol 31: 469–501CrossRefGoogle Scholar
  2. 2.
    Crawley JN, Corwin RL (1994) Biological actions of cholecystokinin. Peptides 15: 731–755PubMedCrossRefGoogle Scholar
  3. 3.
    Benedetti F (1997) Cholecystokmm type A and type B receptors and their modulation of opioid analgesia. News Physiol Sci 12. 263–268Google Scholar
  4. 4.
    Stengaard-Pedersen K, Larsson LI (1981) Localization and opiate receptor binding of enkephalin, CCK and ACTH/beta-endorphin in the rat central nervous system. Peptides 1. 3–19Google Scholar
  5. 5.
    Gall C, Lauterborn J, Burks D, Seroogy K (1987) Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain Brain Res 403. 403–408Google Scholar
  6. 6.
    Gibbins IL, Furness JB, Costa M (1987) Pathway-specific patterns of coexistence of substance P, calcitonin gene-related peptide, cholecystokinin and dynorphm in neurons of the dorsal root ganglia of the guinea pig. Cell Tissue Res 248. 417–437PubMedCrossRefGoogle Scholar
  7. 7.
    Faris PL, Komisaruk BR, Watkins LR, Mayer DJ (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219: 310–312PubMedCrossRefGoogle Scholar
  8. 8.
    Itoh S, Katsuura G, Maeda Y (1982) Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat. Eur J Pharmacol 80. 421–425PubMedCrossRefGoogle Scholar
  9. 9.
    Xu X-J, Puke MJC, Verge VMK, Wiesenfeld-Hallin Z, Hughes J, Hokfelt T (1993) Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathie pain in the rat Neurosci Lett 152. 129–132Google Scholar
  10. 10.
    Ghilardi JR, Allen CJ, Vigna SR, McVey DC, Mantyh PW (1992) Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate-CCK analgesic interactions. J Neurosci 12: 4854–4866PubMedGoogle Scholar
  11. 11.
    Stanfa LC, Dickenson AH, Xu X-J, Wiesenfeld-Hallin Z (1994) Cholecystokinin and morphine analgesia. variations on a theme. Trends Pharmacol Sci 15: 65–66PubMedCrossRefGoogle Scholar
  12. 12.
    Baber NS, Dourish CT, Hill DR (1989) The role of CCK, caerulein, and CCK antagonists m nociception. Pain 39. 307–328PubMedCrossRefGoogle Scholar
  13. 13.
    Wang J, Ren M, Han J (1992) Mobilization of calcium from intracellular stores as one of the mechanisms underlying the antiopioid effects of cholecystokinin octapeptide. Peptides 13.947–951Google Scholar
  14. 14.
    North RA (1989) Drug receptors and the inhibition of nerve cells. Br J Pharmacol 98: 1328Google Scholar
  15. 15.
    Vanderah TW, Lai J, Yamamura HI, Porreca F (1994) Antisense oligonucleotide to the CCK-B receptor produces naltrindole-and (LeuS) enkephalin antiserum-sensitive enhancement of morphine antinociception. NeuroReport 5.2601–2605Google Scholar
  16. 16.
    Ossipov MH, Kovelowski CJ, Porreca F (1995) The increase in potency produced by carrageenan-induced inflammation is blocked by naltrindole, a selective delta opioid antagonist Neurosci Lett 184: 173–176Google Scholar
  17. 17.
    Watkins LR, Kmscheck IB, Kaufman EFS, Miller J, Frenk H, Mayer DJ (1985) Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opioids. Brain Res 327: 181–190PubMedCrossRefGoogle Scholar
  18. 18.
    Dourish CT, Clark ML, Iversen SD (1988) Analgesia induced by restraint stress is attenuated by CCK and enhanced by the CCK antagonists MK-329, L-365260 and CR-1409. Soc Neurosci Abstr 14: 120Google Scholar
  19. 19.
    Xu X-J, Hao J-X, Seiger A, Hughes J, Hokfelt T, Wiesenfeld-Hallin Z (1994) Chronic pain-related behaviors in spinally injured rats: evidence for functional alterations of the endogenous cholecystokinin and opioid systems. Pain 56.271–277Google Scholar
  20. 20.
    Valverde O, Maldonado R, Fournie-Zaluski MC, Roques BP (1994) Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270: 77–88PubMedGoogle Scholar
  21. 21.
    Zhou Y, Sun YH, Han JS (1993) Increased release of immunoreactive CCK-8 by electroacupuncture and enhancement of electroacupuncture analgesia by CCK-8 antagonist in rat spinal cord. Neuropeptides 24: 139–144PubMedCrossRefGoogle Scholar
  22. 22.
    Benedetti F, Amanzio M, Maggi G (1995) Potentiation of placebo analgesia by proglumide Lancet 346. 1231Google Scholar
  23. 23.
    Benedetti F (1996) The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia Pain 64: 535–543Google Scholar
  24. 24.
    Xu X-J, Hokfelt T, Hughes J, Wiesenfeld-Hallin Z (1994) The CCK-B antagonists Ci988 enhances the reflex-depressive effect of morphine in axotomized rats. NeuroReport 5: 718–720Google Scholar
  25. 25.
    Dourish CT, O’Neill MF, Schaeffer LW, Siegl PKS, Iversen SD (1990) The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey. J Pharmacol Exp Ther255: 1158–1165Google Scholar
  26. 26.
    Price DD, Von der Gruen A, Miller J, Rafii A, Price C (1985) Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokmm antagonist. Anaesth Analg 64: 801–806CrossRefGoogle Scholar
  27. 27.
    Lavigne GJ, Hargreaves KM, Schmidt EA, Dionne RA (1989) Proglumide potentiates morphine analgesia for acute postsurgical pain. Clin Pharmacol Ther 45: 666–673PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag Italia, Milano 1999

Authors and Affiliations

  • M. Amanzio
  • F. Benedetti

There are no affiliations available

Personalised recommendations